A b5 composition having thickening barrier and repair efficacy and its use in cosmetics

Abstract

The application provides a B5 composition with thickening barrier and repair effects and application thereof in cosmetics. A hydrolyzed Myrtus communis leaf extract raw material, panthenol and carboxymethyl chitosan are compounded to construct a three-section time sequence repair system of "energy repair-immune repair-regeneration repair", and the three are compounded to have a synergistic effect in reducing expression of inflammatory factors, improving expression of IVL and LOR, and promoting secretion of type I collagen, and have effects of soothing, repairing, anti-aging, improving skin redness, improving transepidermal water loss, repairing postoperative damaged skin in medical aesthetics, and repairing barrier damaged skin.

Description

Technical Field

[0001] This invention relates to the field of daily chemical technology, and in particular to a B5 composition with barrier-thickening and repairing effects and its application in cosmetics. Background Technology

[0002] In recent years, products containing high concentrations of retinol and acids have been highly regarded in the field of anti-aging. However, these ingredients are very likely to cause contact dermatitis, leading to skin barrier damage, redness, stinging, and exacerbation of transepidermal water loss (TEWL).

[0003] Current soothing and repairing ingredients, such as ceramides and bisabolol, are mostly limited to single-target repair, such as simply replenishing intercellular lipids or simply inhibiting inflammatory factors. However, skin damage is a complex cascade process that includes early immune inflammatory storms, mid-stage cellular mitochondrial energy depletion, and late-stage matrix protein loss. Single-target repair products have limited efficacy in repairing the skin. Summary of the Invention

[0004] Therefore, the technical problem to be solved by the present invention is to provide a B5 composition with barrier thickening and repairing effects and its application in cosmetics. The components of the B5 composition provided in this application interact with each other and have a synergistic effect in reducing the expression of inflammatory factors, increasing the expression of IVL and LOR, and promoting the secretion of type I collagen. It can be used for soothing, repairing and anti-aging.

[0005] This application provides a B5 composition with barrier-thickening and repairing effects, comprising: hydrolyzed myrtle leaf extract, panthenol, and carboxymethyl deacetylated chitosan;

[0006] The mass ratio of the hydrolyzed myrtle leaf extract raw material, panthenol, and carboxymethyl deacetylated chitosan is 0.001~5:0.2~10:0.001~0.5.

[0007] The B5 composition provided in this application includes hydrolyzed myrtle (Myrtus communis) leaf extract, which comprises hydrolyzed myrtle (Myrtus communis) leaf extract. The English name for hydrolyzed myrtle (Myrtus communis) leaf extract is HYDROLYZED MYRTUS COMMUNISLEAF EXTRACT, which is a hydrolyzed extract of myrtle leaves and includes oligogalacturonic acid active ingredients. It has the effect of improving skin aging and stress conditions, such as sensitivity, wrinkles, and dullness. This application does not limit the hydrolyzed myrtle (Myrtus communis) leaf extract raw material; commercially available products are acceptable.

[0008] In some specific implementations, the hydrolyzed myrtle (Myrtus communis) leaf extract raw material comprises 2.0 wt% to 10.0 wt% hydrolyzed myrtle (Myrtus communis) leaf extract; 5.0 wt% to 15.0 wt% 1,2-pentanediol; and the balance being water. In some specific implementations, the hydrolyzed myrtle (Myrtus communis) leaf extract raw material comprises 2.5 wt% to 8 wt% hydrolyzed myrtle (Myrtus communis) leaf extract; 8.0 wt% to 12.0 wt% 1,2-pentanediol; and the balance being water. In some specific implementations, the hydrolyzed myrtle (Myrtus communis) leaf extract raw material comprises 2.8 wt% to 4.2 wt% hydrolyzed myrtle (Myrtus communis) leaf extract; 9.0 wt% to 11.0 wt% 1,2-pentanediol; and the balance being water. In some specific implementations, the hydrolyzed myrtle (Myrtus communis) leaf extract raw material comprises 3.5 wt% hydrolyzed myrtle (Myrtus communis) leaf extract; 10.0 wt% 1,2-pentanediol and the balance water.

[0009] The B5 composition provided in this application includes panthenol (also known as provitamin B5), a stable precursor of vitamin B5 (pantothenic acid). After being absorbed by the skin, panthenol is rapidly converted into pantothenic acid, which then participates in the synthesis of coenzyme A. Panthenol not only has excellent skin absorption properties but can also be rapidly converted to pantothenic acid through oxidation. Topical application of panthenol has multiple beneficial skincare effects, including: i) promoting the synthesis of ceramides and cholesterol in the stratum corneum, repairing the skin barrier, and reducing transepidermal water loss (TEWL); ii) activating fibroblast activity, promoting collagen and elastin synthesis, and accelerating tissue healing; iii) inhibiting cyclooxygenase (COX-2) activity, reducing inflammatory mediators such as prostaglandins, and relieving skin redness, burning, and stinging; iv) upregulating the expression of filaggrin (FLG) and transglutaminase 1 (TGM1) genes in keratinocytes, enhancing the integrity of the stratum corneum. In this application, panthenol is dextro-panthenol (D-panthenol), with CAS number 81-13-0. This application does not impose any special restrictions on the source of the panthenol; any product purchased from the market is acceptable.

[0010] The B5 composition provided in this application includes carboxymethyl deacetylated chitosan, also known as carboxymethyl chitosan, which is a water-soluble derivative obtained by carboxymethylation modification of chitosan. Carboxymethyl deacetylated chitosan has good biocompatibility, biodegradability, and antibacterial properties, and can promote the proliferation of keratinocytes and fibroblasts, accelerating epidermal repair. In some specific implementations, the number average molecular weight of the carboxymethyl deacetylated chitosan is 100,000 (10w) Da to 800,000 (80w) Da, preferably 20w Da to 50w Da, and more preferably 25w Da to 40w Da. This number average molecular weight of carboxymethyl deacetylated chitosan combines good film-forming density with moderate bioactivity. By forming a biomimetic breathable film on the skin surface to physically isolate external stimuli, and by adsorbing a large number of water molecules through its cationic polysaccharide molecular structure, it achieves the dual effects of moisturizing and barrier maintenance, realizing the synergistic unity of physical barrier and biological repair. This application does not impose any special restrictions on the source of the carboxymethyl deacetylated chitosan; it can be a product with CAS number 83512-85-0, which can be purchased on the market.

[0011] This application combines hydrolyzed myrtle (Myrtus communis) leaf extract, panthenol, and carboxymethyl deacetylated chitosan. The hydrolyzed myrtle (Myrtus communis) leaf extract can target and activate the longevity protein SIRT-1, thereby enhancing mitochondrial activity and cellular energy (ATP) production. Panthenol has multiple beneficial skincare effects, including repairing the skin barrier, reducing transepidermal water loss, relieving skin redness, burning and stinging, and strengthening the stratum corneum. Carboxymethyl deacetylated chitosan possesses both good film-forming density and moderate biological activity, achieving a synergistic effect between physical barrier function and biological repair. The combined use of these three ingredients has a synergistic effect in reducing inflammatory factor expression, increasing IVL and LOR expression, and promoting type I collagen secretion. Experimental results showed that replacing the hydrolyzed myrtle (Myrtus communis) leaf extract with other plant leaf extracts, such as centella asiatica leaf extract, significantly reduced the effects on reducing inflammatory factor expression, increasing IVL and LOR expression, and promoting type I collagen secretion. Alternatively, replacing carboxymethyl deacetylated chitosan with other polysaccharides, such as sodium hyaluronate with a similar number-average molecular weight, significantly reduced the effects on reducing inflammatory factor expression, increasing IVL and LOR expression, and promoting type I collagen secretion.

[0012] In some specific implementations, the mass ratio of the hydrolyzed myrtle (Myrtus communis) leaf extract, panthenol, and carboxymethyl deacetylated chitosan is 0.001~5:0.2~10:0.001~0.5, preferably 0.01~2:0.3~5:0.002~0.2, more preferably 0.02~0.2:0.4~1:0.004~0.02, for example, 0.02:1:0.004 or 0.2:0.4:0.02, etc.

[0013] The B5 composition provided in this application can construct a complete time-series repair chain, including the following three stages:

[0014] Phase 1 (Energy Repair: Revitalizing Mitochondria and Strengthening the Energy Foundation): Hydrolyzed Myrtus communis leaf extract can efficiently target and activate the longevity protein SIRT-1. Combined with the cell metabolism-promoting effect of panthenol, it synergistically revitalizes the mitochondrial function of damaged cells, rapidly increasing intracellular ATP synthesis and providing an energy source for subsequent repair.

[0015] The second stage (immune repair: rapid inflammation relief and precise regulation of immune response): Carboxymethyl deacetylated chitosan forms a biomimetic breathable membrane on the skin surface, physically isolating external stimuli; at the same time, it works synergistically with panthenol to rapidly inhibit the secretion of inflammatory factors (such as TNF-α, IL-6, etc.) by immune cells such as macrophages. On the basis of a solid energy foundation, it blocks abnormal chemotaxis and vasodilation of immune cells, and rapidly relieves the inflammatory microenvironment.

[0016] The third stage (regeneration and repair: comprehensive reconstruction of the epidermal barrier and dermal matrix): With sufficient energy and the inflammation subsided, a large number of energetic fibroblasts and keratinocytes proliferate. The three work together to promote the expression of epidermal barrier proteins (IVL, LOR) to rebuild the keratinized capsule. The three work together to promote the generation of epidermal barrier proteins and dermal matrix, achieving comprehensive reconstruction from top to bottom.

[0017] The B5 composition provided in this application has soothing, repairing, anti-aging, and skin redness and transepidermal water loss-reducing effects, as well as repairing damaged skin after cosmetic procedures and repairing skin with a damaged skin barrier. It can be used to prepare products with corresponding effects. Specifically, the B5 composition provided in this application can increase mitochondrial membrane potential and activate cellular energy metabolism; it can inhibit the release of pro-inflammatory factors (such as IL-8) and soothe redness, burning, and stinging; it can promote the expression of inner laminarin (IVL) and lobe laminarin (LOR), repair the skin barrier, and reduce TEWL values; it can promote the secretion of type I collagen, improve skin firmness and elasticity, and achieve full-layer repair from the epidermis to the dermis.

[0018] The present invention also provides a product comprising: the B5 composition described in the above technical solution.

[0019] In some embodiments of the present invention, the above-mentioned products include, but are not limited to, personal care products, pharmaceuticals, etc. Those skilled in the art will understand that, in addition to the B5 composition described in the above technical solutions, it also includes other excipients, such as pharmaceutical excipients or excipients for personal care products.

[0020] The products provided in this application can be applied to the keratinized tissue of mammals, such as to human skin, in various forms, including but not limited to solutions, suspensions, lotions, creams, gels, lakes, stick products, pens, sprays, aerosols, ointments, cleaning liquid detergents and solid sticks, shampoos and hair conditioners, pastes, foams, powders, mousses, shaving creams, wipes, strips, patches, electric patches, wound dressings and adhesive bandages, hydrogels, film-forming products, masks and skin masks, etc.

[0021] In some embodiments of the present invention, the personal care products include: basic care products and / or makeup products.

[0022] In some embodiments of the present invention, the cosmetic products include, but are not limited to:

[0023] (1) Base makeup:

[0024] Foundation / cream: Used to even out skin tone and cover blemishes;

[0025] BB cream / CC cream: A lightweight base makeup product that combines skincare and makeup application;

[0026] Concealer / pen: Used to cover up specific areas such as pimples and dark circles;

[0027] Loose powder / setting powder: Sets makeup and reduces facial shine.

[0028] (2) Eye makeup:

[0029] Eyeshadow: Adds color and dimension to the eyes;

[0030] Eyeliner pencil / liquid / gel: Used to draw lines on the eyes, making them look more vibrant;

[0031] Mascara: Lengthens and thickens eyelashes, enhancing the depth of the eyes;

[0032] Eyebrow pencil / powder / gel: Fill in gaps in eyebrows and create the ideal eyebrow shape.

[0033] (3) Cheek makeup:

[0034] Blush: Adds natural color to the cheeks and improves complexion;

[0035] Contouring powder / stick: Use shading techniques to make facial contours more three-dimensional;

[0036] (4) Lip makeup:

[0037] Lipstick / lip gloss / lip tint: to change or emphasize the color of the lips;

[0038] Lip liner: Defines the clear outline of the lips and prevents lipstick from bleeding.

[0039] (5) Multifunctional cosmetics:

[0040] Highlighter sticks / liquids / powders: Highlight high points on the face (such as the bridge of the nose and cheekbones) to create a luminous effect.

[0041] In addition, there are products designed specifically for special occasions, such as waterproof and sweatproof eyeliners and long-lasting, non-fading lipsticks.

[0042] In some embodiments of the present invention, the basic care products include, but are not limited to:

[0043] Facial cleanser: Gently removes dirt, oil, and makeup residue from the face;

[0044] Cleansing oil / cleansing water / cleansing balm: specially designed to thoroughly remove makeup, especially waterproof cosmetics;

[0045] Toner / lotion: Used after cleansing, it can further cleanse the skin's surface of residue, while replenishing the skin's moisture, restoring the skin's pH balance, and laying a good foundation for the absorption of subsequent skin care products;

[0046] Serum: Contains a high concentration of active ingredients, providing deep nourishment and repair for specific skin problems (such as anti-aging, moisturizing, whitening, etc.);

[0047] Eye cream: Specially designed for the sensitive area around the eyes, it has the effects of reducing fine lines and dark circles and firming the skin around the eyes. The texture is usually light and easily absorbed.

[0048] Day / night lotion or cream: It has functions such as protection, repair and nourishment, and promotes cell regeneration. It can provide the skin with the necessary moisture and lock in the replenished moisture.

[0049] Sunscreen: Used for ultraviolet protection and prevention of photoaging, etc.

[0050] Face masks: provide extra nourishment and care for the skin, such as hydration, pore cleansing, or brightening of skin tone.

[0051] Specifically, the products provided in this application include, but are not limited to, soothing and repairing toners, soothing and repairing lotions, soothing and repairing creams, soothing and repairing serums, soothing and repairing gels, and soothing and repairing masks. In some specific implementations, the products include 0.1wt% to 15wt% of the B5 composition described in the above-mentioned technical solutions, preferably 0.5wt% to 14.5wt% of the B5 composition described in the above-mentioned technical solutions, and more preferably 1wt% to 14wt% of the B5 composition described in the above-mentioned technical solutions.

[0052] In some specific implementations, the product is a toner, including:

[0053] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0054] 0.1wt%~15wt% humectant;

[0055] 0.0001wt%~1wt% of metal ion chelating agent;

[0056] 0.01wt%~10wt% of soothing ingredients;

[0057] Preservatives ranging from 0.001 wt% to 5 wt%;

[0058] And the remaining water.

[0059] The moisturizer is used to hydrate the skin and improve dryness, peeling, and tightness. In some specific implementations, the moisturizer includes, but is not limited to, small-molecule polyol moisturizers, such as glycerin, butylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol, propylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, etc.; amino acid moisturizers, such as betaine, proline, serine, arginine, sodium PCA (sodium pyrrolidone carboxylate), etc.; high-molecular-weight polysaccharide moisturizers, such as sodium polyglutamate, sodium hyaluronate, hydrolyzed hyaluronic acid, panthenol hyaluronic acid, β-glucan, trehalose, tremella polysaccharide, panthenol-based trehalose, etc.; and other natural moisturizers, such as hydrolyzed collagen, hydrolyzed keratin, polyethylene glycol-8, etc., which can be one or more of these, preferably butylene glycol, glycerin, and sodium polyglutamate. In some specific implementations, the content of the humectant is preferably 0.5wt% to 14wt%, more preferably 1wt% to 13wt%.

[0060] In this application, the metal ion chelating agent is used to complex heavy metal ions such as calcium, magnesium, and iron in the toner, thereby improving the storage stability of the toner. In some specific implementations, the metal ion chelating agent includes, but is not limited to, disodium EDTA, tetrasodium EDTA, disodium calcium EDTA, gluconolactone, sodium gluconate, sodium phytate, dihydroxyethylglycine, tetrasodium glutamate diacetate, trisodium methylglycine diacetate, sodium citrate, citric acid, etc., preferably disodium EDTA. In some specific implementations, the content of the metal ion chelating agent is preferably 0.001wt%~0.5wt%, more preferably 0.01wt%~0.1wt%.

[0061] In this application, the soothing ingredients function to relieve redness and reduce formulation irritation. In some specific implementations, the soothing ingredients include, but are not limited to, sodium polyglutamate, allantoin, betaine, ectoine, glycyrrhetinic acid, dipotassium glycyrrhizate, panthenol acetate, centella asiatica extract, asiaticoside, hydroxyasiaticoside, purslane extract, gentian root extract, chamomile extract, calendula extract, bisabolol, chamomile oil, scutellaria baicalensis root extract, white willow bark extract, urocanic acid, ceramides NP / AP / EO, phytosterols, etc., and may be one or more of these, preferably sodium polyglutamate, allantoin, and betaine. In some specific implementations, the content of the soothing ingredients is preferably 0.05wt%~9.5wt%, more preferably 0.1wt%~9wt%.

[0062] In this application, the preservative is used to inhibit bacteria and improve the stability of the formulation. In some specific implementations, the preservative includes, but is not limited to, p-hydroxyacetophenone, 1,3-butanediol, 1,2-hexanediol, phenylethyl resorcinol, capryloyl hydroxamic acid, 1,2-pentanediol, ethylhexylglycerin, hexanediol, heptaethylenediol, etc., and may be one or more of these, preferably p-hydroxyacetophenone, 1,3-butanediol, and 1,2-hexanediol. In some specific implementations, the content of the preservative is preferably 0.01wt% to 4wt%, more preferably 0.1wt% to 3wt%.

[0063] In some specific implementations, the toner includes:

[0064] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0065] 0.1wt%~10wt% of butanediol;

[0066] 0.1wt%~10wt% glycerol;

[0067] 0.01wt%~1wt% sodium polyglutamate;

[0068] 0.0001wt%~1wt% of disodium EDTA;

[0069] Allantoin at concentrations of 0.001 wt% to 5 wt%;

[0070] 0.001wt%~5wt% betaine;

[0071] 0.001wt%~2wt% of p-hydroxyacetophenone;

[0072] 0.001wt%~5wt% of 1,3-butanediol;

[0073] 0.001wt%~5wt% of 1,2-hexanediol;

[0074] And the remaining water.

[0075] In some specific implementations, the toner includes:

[0076] 0.5wt%~10wt% of the B5 composition described in the above technical solution;

[0077] 1wt%~5wt% butanediol;

[0078] 1wt%~5wt% glycerol;

[0079] 0.01wt%~0.1wt% sodium polyglutamate;

[0080] 0.001wt%~0.1wt% of disodium EDTA;

[0081] 0.01wt%~1wt% allantoin;

[0082] 0.01wt%~3wt% betaine;

[0083] 0.01wt%~1wt% of p-hydroxyacetophenone;

[0084] 0.01wt%~1wt% of 1,3-butanediol;

[0085] 0.01wt%~1wt% of 1,2-hexanediol;

[0086] And the remaining water.

[0087] In some specific implementations, the toner includes:

[0088] 0.62 wt% of the B5 composition described in the above technical solution;

[0089] 4 wt% butanediol;

[0090] 3wt% glycerin;

[0091] 0.05 wt% sodium polyglutamate;

[0092] 0.03wt% disodium EDTA;

[0093] 0.1 wt% allantoin;

[0094] 1.5wt% betaine;

[0095] 0.5 wt% p-hydroxyacetophenone;

[0096] 1 wt% of 1,3-butanediol;

[0097] 0.5 wt% 1,2-hexanediol;

[0098] And the remaining water.

[0099] In some specific implementations, the product is an emulsion, including:

[0100] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0101] 0.1wt%~10wt% humectant;

[0102] 0.001wt%~5wt% of metal ion chelating agent;

[0103] Preservatives ranging from 0.001 wt% to 5 wt%;

[0104] Thickener: 0.001wt%~1wt%;

[0105] Oils and fats ranging from 0.01 wt% to 5 wt%;

[0106] 0.01wt%~5wt% emulsifier;

[0107] pH adjuster, 0.001wt%~1wt%;

[0108] And the remaining water.

[0109] The moisturizer is used to hydrate the skin and improve dryness, peeling, and tightness. In some specific implementations, the moisturizer includes, but is not limited to, small-molecule polyol moisturizers, such as glycerin, butylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol, propylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, etc.; amino acid moisturizers, such as betaine, proline, serine, arginine, sodium PCA (sodium pyrrolidone carboxylate), etc.; high-molecular-weight polysaccharide moisturizers, such as sodium polyglutamate, sodium hyaluronate, hydrolyzed hyaluronic acid, panthenol hyaluronic acid, β-glucan, trehalose, tremella polysaccharide, panthenol-based trehalose, etc.; and other natural moisturizers, such as hydrolyzed collagen, hydrolyzed keratin, polyethylene glycol-8, etc., which can be one or more of these, preferably glycerin. In some specific implementations, the content of the moisturizer is preferably 0.5wt%~9wt%, more preferably 1wt%~8wt%.

[0110] In this application, the metal ion chelating agent is used to complex heavy metal ions such as calcium, magnesium, and iron in the emulsion, thereby improving the storage stability of the emulsion. In some specific implementations, the metal ion chelating agent includes, but is not limited to, disodium EDTA, tetrasodium EDTA, disodium calcium EDTA, gluconolactone, sodium gluconate, sodium phytate, dihydroxyethylglycine, tetrasodium glutamate diacetate, trisodium methylglycine diacetate, sodium citrate, citric acid, etc., preferably disodium EDTA. In some specific implementations, the content of the metal ion chelating agent is preferably 0.01wt%~3wt%, more preferably 0.1wt%~1wt%.

[0111] In this application, the preservative is used to inhibit bacteria and improve the stability of the formulation. In some specific implementations, the preservative includes, but is not limited to, p-hydroxyacetophenone, 1,3-butanediol, 1,2-hexanediol, phenylethyl resorcinol, capryloyl hydroxamic acid, 1,2-pentanediol, ethylhexylglycerin, hexanediol, heptaethylenediol, etc., and may be one or more of these, preferably p-hydroxyacetophenone, 1,2-hexanediol, and 1,2-pentanediol. In some specific implementations, the content of the preservative is preferably 0.01wt% to 4wt%, more preferably 0.1wt% to 3wt%.

[0112] In this application, the thickener is used to increase the viscosity of the emulsion and improve the skin feel after application. In some specific implementations, the thickener includes, but is not limited to, acrylic thickeners, such as carbomer, acrylic (ester) / C10-30 acid cholesterol / stearyl ester copolymers, polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, etc.; polyamide thickeners, such as polyacrylamide / C13-14 isoparaffin / laurate polyether-7, acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate-80, etc.; natural polysaccharide thickeners, such as xanthan gum, guar gum and modified guar gum, sodium hyaluronate, sodium alginate, tremella polysaccharide, etc.; cellulose thickeners, such as hydroxyethyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, etc., which can be one or more of these, preferably carbomer. In some specific implementations, the content of the thickener is preferably 0.005wt% to 0.5wt%, more preferably 0.01wt% to 0.1wt%.

[0113] In this application, the oil is used to optimize the emulsification stability of the emulsion and can also form a breathable oil film on the stratum corneum to alleviate peeling and dryness. In some specific implementations, the oil includes, but is not limited to, synthetic ester oils, such as triglycerides (ethylhexanoate), isopropyl myristate, isononyl isononanoate, isopropyl palmitate, caprylic / capric triglycerides, etc.; silicone oils, such as polydimethylsiloxane, cyclopentasiloxane, polydimethylsiloxane alcohol, etc.; natural oils, such as shea butter, squalane, jojoba oil, etc.; and fatty alcohols, such as cetearyl alcohol, cetyl alcohol, etc., which can be one or more of these, preferably triglycerides (ethylhexanoate) and polydimethylsiloxane. In some specific implementations, the content of the oil is preferably 0.05wt%~3wt%, more preferably 0.1wt%~2wt%.

[0114] In this application, the emulsifier is used to form an emulsion and to stabilize the emulsion. In some specific implementations, the emulsifier includes, but is not limited to, nonionic emulsifiers such as MONTANOV 202 emulsifier, glyceryl stearate and polyglyceryl-3 stearate, cetearyl ether-20, cetearyl ether-10, sucrose stearate, sucrose palmitate, polysorbates, Tween-80, Tween-60, etc.; polyacrylamide emulsifiers such as SEPIGEL 30, Simulgel 600, etc.; and anionic emulsifiers such as magnesium stearate, sodium dodecylbenzene sulfonate, etc., which can be one or more of these, preferably MONTANOV 202 emulsifier, SEPIGEL 30 emulsifier, etc. In some specific implementations, the content of the emulsifier is preferably 0.05wt% to 3wt%, more preferably 0.1wt% to 2wt%.

[0115] In this application, the pH adjuster is used to neutralize the thickener system, allowing the emulsion to reach a suitable consistency. In some specific implementations, the pH adjuster includes, but is not limited to, alkanolamine pH adjusters, such as aminomethylpropanol complexes, triethanolamine, diethanolamine, and monoethanolamine; and organic acid and salt pH adjusters, such as citric acid and sodium citrate, lactic acid and sodium lactate, malic acid, etc., and may be one or more of these, preferably an aminomethylpropanol complex comprising 95% aminomethylpropanol and 9% water. In some specific implementations, the content of the pH adjuster is preferably 0.005wt% to 0.5wt%, more preferably 0.01wt% to 0.1wt%.

[0116] In some specific implementations, the emulsion includes:

[0117] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0118] 0.1wt%~10wt% glycerol;

[0119] 0.001wt%~5wt% of disodium EDTA;

[0120] 0.001wt%~1wt% of carbomer;

[0121] 0.01wt%~5wt% of glycerol tri(ethylhexanoate);

[0122] 0.01wt%~5wt% of polydimethylsiloxane;

[0123] 0.01wt%~3wt% of MONTANOV 202 emulsifier;

[0124] 0.01wt%~3wt% of SEPIGEL 30 emulsifier;

[0125] 0.01wt%~3wt% of p-hydroxyacetophenone;

[0126] 0.01wt%~3wt% of 1,2-pentanediol;

[0127] 0.01wt%~3wt% of 1,2-hexanediol;

[0128] 0.001wt%~1wt% aminomethylpropanol complex;

[0129] And the remaining water.

[0130] In some specific implementations, the emulsion includes:

[0131] 0.1wt%~10wt% of the B5 composition described in the above technical solution;

[0132] 0.1wt%~5wt% glycerol;

[0133] 0.01wt%~3wt% of disodium EDTA;

[0134] 0.005wt%~0.5wt% of carbomer;

[0135] 0.1wt%~3wt% of triglyceride (ethylhexanoate);

[0136] 0.1wt%~3wt% of polydimethylsiloxane;

[0137] 0.05wt%~2wt% MONTANOV 202 emulsifier;

[0138] 0.05wt%~1wt% of SEPIGEL 30 emulsifier;

[0139] 0.05wt%~1wt% of p-hydroxyacetophenone;

[0140] 0.1wt%~2wt% of 1,2-pentanediol;

[0141] 0.1wt%~1wt% of 1,2-hexanediol;

[0142] 0.005wt%~0.5wt% of aminomethylpropanol compound;

[0143] And the remaining water.

[0144] In some specific implementations, the emulsion includes:

[0145] 1.024 wt% of the B5 composition described in the above technical solution;

[0146] 3wt% glycerin;

[0147] 1 wt% disodium EDTA;

[0148] 1 wt% carbomer;

[0149] 1 wt% triglyceride (ethylhexanoate);

[0150] 1 wt% polydimethylsiloxane;

[0151] 1 wt% MONTANOV 202 emulsifier;

[0152] 0.8wt% SEPIGEL 30 emulsifier;

[0153] 0.3wt% p-hydroxyacetophenone;

[0154] 1 wt% of 1,2-pentanediol;

[0155] 0.5 wt% 1,2-hexanediol;

[0156] 0.05 wt% aminomethylpropanol compound;

[0157] And the remaining water.

[0158] In some specific implementations, the product is a face cream, including:

[0159] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0160] 0.1wt%~15wt% humectant;

[0161] Thickener: 0.001wt%~1wt%;

[0162] Emulsifiers ranging from 0.01 wt% to 15 wt%;

[0163] Oils and fats ranging from 0.01 wt% to 20 wt%;

[0164] 0.0001wt%~1wt% of metal ion chelating agent;

[0165] Preservatives ranging from 0.001 wt% to 5 wt%;

[0166] pH adjuster, 0.001wt%~1wt%;

[0167] And the remaining water.

[0168] The moisturizer is used to hydrate the skin and improve dryness, peeling, and tightness. In some specific implementations, the moisturizer includes, but is not limited to, small-molecule polyol moisturizers, such as glycerin, butylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol, propylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, etc.; amino acid moisturizers, such as betaine, proline, serine, arginine, sodium PCA (sodium pyrrolidone carboxylate), etc.; high-molecular-weight polysaccharide moisturizers, such as sodium polyglutamate, sodium hyaluronate, hydrolyzed hyaluronic acid, panthenol hyaluronic acid, β-glucan, trehalose, tremella polysaccharide, panthenol-based trehalose, etc.; and other natural moisturizers, such as hydrolyzed collagen, hydrolyzed keratin, polyethylene glycol-8, etc., which can be one or more of these, preferably glycerin and butylene glycol. In some specific implementations, the content of the humectant is preferably 0.5wt% to 14wt%, more preferably 1wt% to 13wt%.

[0169] In this application, the metal ion chelating agent is used to complex heavy metal ions such as calcium, magnesium, and iron in the face cream, thereby improving the storage stability of the face cream. In some specific implementations, the metal ion chelating agent includes, but is not limited to, disodium EDTA, tetrasodium EDTA, disodium calcium EDTA, gluconolactone, sodium gluconate, sodium phytate, dihydroxyethylglycine, tetrasodium glutamate diacetate, trisodium methylglycine diacetate, sodium citrate, citric acid, etc., preferably disodium EDTA. In some specific implementations, the content of the metal ion chelating agent is preferably 0.005wt%~0.5wt%, more preferably 0.01wt%~0.1wt%.

[0170] In this application, the preservative is used to inhibit bacteria and improve the stability of the formulation. In some specific implementations, the preservative includes, but is not limited to, p-hydroxyacetophenone, 1,3-butanediol, 1,2-hexanediol, phenylethyl resorcinol, capryloyl hydroxamic acid, 1,2-pentanediol, ethylhexylglycerin, hexanediol, heptaethylenediol, etc., and may be one or more of these, preferably p-hydroxyacetophenone, 1,2-hexanediol, and 1,3-butanediol. In some specific implementations, the content of the preservative is preferably 0.01wt% to 4wt%, more preferably 0.1wt% to 3wt%.

[0171] In this application, the thickener is used to increase the viscosity of the face cream and improve the application feel. In some specific implementations, the thickener includes, but is not limited to, acrylic thickeners, such as carbomer, acrylic (ester) / C10-30 acid cholesterol / stearyl ester copolymers, polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, etc.; polyamide thickeners, such as polyacrylamide / C13-14 isoparaffin / laurate polyether-7, acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate-80, etc.; natural polysaccharide thickeners, such as xanthan gum, guar gum and modified guar gum, sodium hyaluronate, sodium alginate, tremella polysaccharide, etc.; cellulose thickeners, such as hydroxyethyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, etc., which can be one or more of these, preferably xanthan gum. In some specific implementations, the content of the thickener is preferably 0.005wt% to 0.7wt%, more preferably 0.01wt% to 0.5wt%.

[0172] In this application, the oils are used to optimize the emulsification stability of face creams and can also form a breathable oil film on the stratum corneum to alleviate peeling and dryness. In some specific implementations, the oils include, but are not limited to, synthetic ester oils, such as triglycerides (ethylhexanoate), isopropyl myristate, isononyl isononanoate, isopropyl palmitate, caprylic / capric triglycerides, etc.; silicone oils, such as polydimethylsiloxane, cyclopentasiloxane, polydimethylsiloxane alcohol, etc.; natural oils, such as shea butter, squalane, jojoba oil, etc.; and fatty alcohols, such as cetearyl alcohol, cetyl alcohol, etc., which can be one or more of these, preferably cetearyl alcohol, shea butter, isopropyl myristate, and polydimethylsiloxane. In some specific implementations, the content of the oils is preferably 1wt%~18wt%, more preferably 5wt%~15wt%.

[0173] In this application, the emulsifier is used to stabilize the face cream. In some specific implementations, the emulsifier includes, but is not limited to, nonionic emulsifiers, such as MONTANOV 202 emulsifier, glyceryl stearate and polyglyceryl-3 stearate, cetearyl alcohol ether-20, cetearyl alcohol ether-10, sucrose stearate, sucrose palmitate, polysorbate esters, Tween-80, Tween-60, sucrose stearate / cetearyl glucoside / cetyl alcohol, glyceryl stearate, etc.; polyacrylamide emulsifiers, such as SEPIGEL 30, Simulgel 600, etc.; anionic emulsifiers, such as magnesium stearate, sodium dodecylbenzene sulfonate, etc., which can be one or more of these, preferably sucrose stearate / cetearyl glucoside / cetyl alcohol and glyceryl stearate. In some specific implementations, the content of the emulsifier is preferably 0.1wt% to 10wt%, more preferably 1wt% to 5wt%.

[0174] In this application, the pH adjuster is used to neutralize the thickener system, allowing the cream to reach a suitable consistency. In some specific implementations, the pH adjuster includes, but is not limited to, alkanolamine pH adjusters, such as aminomethylpropanol complexes, triethanolamine, diethanolamine, and monoethanolamine; and organic acid and salt pH adjusters, such as citric acid and sodium citrate, lactic acid and sodium lactate, malic acid, etc., and may be one or more of these, preferably an aminomethylpropanol complex comprising 95% aminomethylpropanol and 9% water. In some specific implementations, the content of the pH adjuster is preferably 0.005wt%~0.5wt%, more preferably 0.01wt%~0.1wt%.

[0175] In some specific implementations, the face cream includes:

[0176] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0177] 0.1wt%~10wt% glycerol;

[0178] 0.1wt%~10wt% of butanediol;

[0179] 0.001wt%~1wt% xanthan gum;

[0180] 0.01wt%~10wt% of sucrose stearate / cetosteryl glucoside / cetyl alcohol;

[0181] 0.01wt%~10wt% cetearyl alcohol;

[0182] 0.01wt%~10wt% glyceryl stearate;

[0183] Shea butter, ranging from 0.01 wt% to 10 wt%.

[0184] 0.01wt%~10wt% isopropyl myristate;

[0185] 0.01wt%~5wt% of polydimethylsiloxane;

[0186] 0.0001wt%~1wt% of disodium EDTA;

[0187] 0.001wt%~5wt% of p-hydroxyacetophenone;

[0188] 0.001wt%~5wt% of 1,3-butanediol;

[0189] 0.001wt%~5wt% of 1,2-hexanediol;

[0190] 0.001wt%~1wt% aminomethylpropanol complex;

[0191] And the remaining water.

[0192] In some specific implementations, the face cream includes:

[0193] 5wt%~13wt% of the B5 composition described in the above technical solution;

[0194] 1wt%~5wt% glycerol;

[0195] 1wt%~5wt% butanediol;

[0196] 0.01wt%~0.5wt% xanthan gum;

[0197] 1wt%~5wt% sucrose stearate / cetosteryl glucoside / cetyl alcohol;

[0198] 1wt%~5wt% cetearyl alcohol;

[0199] 0.1wt%~5wt% glyceryl stearate;

[0200] 1wt%~5wt% of shea butter;

[0201] 1wt%~8wt% isopropyl myristate;

[0202] 1wt%~4wt% of polydimethylsiloxane;

[0203] 0.001wt%~0.5wt% of disodium EDTA;

[0204] 0.1wt%~1wt% of p-hydroxyacetophenone;

[0205] 0.1wt%~3wt% of 1,3-butanediol;

[0206] 0.1wt%~1wt% of 1,2-hexanediol;

[0207] 0.01wt%~0.5wt% of aminomethylpropanol complex;

[0208] And the remaining water.

[0209] In some specific implementations, the face cream includes:

[0210] 10.24 wt% of the B5 composition described in the above technical solution;

[0211] 4wt% glycerol;

[0212] 3wt% butanediol;

[0213] 0.1wt% xanthan gum;

[0214] 2.5 wt% sucrose stearate / cetristyl glucoside / cetyl alcohol;

[0215] 3.0 wt% cetearyl alcohol;

[0216] 1.0 wt% glyceryl stearate;

[0217] 4wt% shea butter;

[0218] 5 wt% isopropyl myristate;

[0219] 3 wt% polydimethylsiloxane;

[0220] 0.03wt% disodium EDTA;

[0221] 0.5 wt% p-hydroxyacetophenone;

[0222] 1 wt% of 1,3-butanediol;

[0223] 0.5 wt% 1,2-hexanediol;

[0224] 0.1 wt% aminomethylpropanol compound;

[0225] And the remaining water.

[0226] In some specific implementations, the product is a facial mask, including:

[0227] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0228] 0.1wt%~10wt% humectant;

[0229] Thickener: 0.001wt%~5wt%;

[0230] 0.01wt%~5wt% emulsifier;

[0231] Oils and fats ranging from 0.01 wt% to 5 wt%;

[0232] Preservatives ranging from 0.001 wt% to 5 wt%;

[0233] pH adjuster, 0.001wt%~1wt%;

[0234] And the remaining water.

[0235] The moisturizer is used to hydrate the skin and improve dryness, peeling, and tightness. In some specific implementations, the moisturizer includes, but is not limited to, small-molecule polyol moisturizers, such as glycerin, butylene glycol, 1,3-butanediol, 1,2-pentanediol, 1,2-hexanediol, propylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, etc.; amino acid moisturizers, such as betaine, proline, serine, arginine, sodium PCA (sodium pyrrolidone carboxylate), etc.; high-molecular-weight polysaccharide moisturizers, such as sodium polyglutamate, sodium hyaluronate, hydrolyzed hyaluronic acid, panthenol hyaluronic acid, β-glucan, trehalose, tremella polysaccharide, panthenol-based trehalose, etc.; and other natural moisturizers, such as hydrolyzed collagen, hydrolyzed keratin, polyethylene glycol-8, etc., which can be one or more of these, preferably glycerin. In some specific implementations, the content of the moisturizer is preferably 0.5wt%~9wt%, more preferably 1wt%~8wt%.

[0236] In this application, the preservative is used to inhibit bacteria and improve the stability of the formulation. In some specific implementations, the preservative includes, but is not limited to, p-hydroxyacetophenone, 1,3-butanediol, 1,2-hexanediol, phenylethyl resorcinol, capryloyl hydroxamic acid, 1,2-pentanediol, ethylhexylglycerin, hexanediol, heptaethylenediol, etc., and may be one or more of these, preferably p-hydroxyacetophenone, 1,2-hexanediol, and 1,3-butanediol. In some specific implementations, the content of the preservative is preferably 0.01wt% to 4wt%, more preferably 0.1wt% to 3wt%.

[0237] In this application, the thickener is used to increase the viscosity of the mask liquid and improve the feel of the skin after application. In some specific implementations, the thickener includes, but is not limited to, acrylic thickeners, such as carbomer, acrylic (ester) / C10-30 acid cholesterol / stearyl ester copolymers, acrylic (ester) / C10-30 alkanol acrylate crosspolymers, polyacrylate crosspolymer-6, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymers, etc.; polyamide thickeners, such as polyacrylamide / C13-14 isoparaffin / lauryl ether-7, acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate-80, etc.; natural polysaccharide thickeners, such as xanthan gum, guar gum and modified guar gum, sodium hyaluronate, sodium alginate, tremella polysaccharide, etc.; cellulose thickeners, such as hydroxyethyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, etc., which can be one or more of these, preferably xanthan gum and acrylic (ester) / C10-30 alkanol acrylate crosspolymers. In some specific implementations, the content of the thickener is preferably 0.005wt% to 0.7wt%, more preferably 0.01wt% to 0.5wt%.

[0238] In this application, the oil is used to optimize the emulsification stability of the mask liquid and can also form a breathable oil film on the stratum corneum to alleviate peeling and dryness. In some specific implementations, the oil includes, but is not limited to, synthetic ester oils, such as triglycerides (ethylhexanoate), isopropyl myristate, isononyl isononanoate, isopropyl palmitate, caprylic / capric triglycerides, etc.; silicone oils, such as polydimethylsiloxane, cyclopentasiloxane, polydimethylsiloxane alcohol, etc.; natural oils, such as shea butter, squalane, jojoba oil, etc.; fatty alcohols, such as cetearyl alcohol, cetyl alcohol, etc., and can be one or more of these, preferably squalane. In some specific implementations, the content of the oil is preferably 1wt%~18wt%, more preferably 5wt%~15wt%.

[0239] In this application, the emulsifier is used to stabilize the facial mask liquid. In some specific implementations, the emulsifier includes, but is not limited to, nonionic emulsifiers, such as MONTANOV 202 emulsifier, glyceryl stearate and polyglyceryl-3 stearate, cetearyl alcohol ether-20, cetearyl alcohol ether-10, sucrose stearate, sucrose palmitate, polysorbate esters, Tween-80, Tween-60, sucrose stearate / cetearyl glucoside / cetyl alcohol, glyceryl stearate, etc.; polyacrylamide emulsifiers, such as SEPIGEL 30, Simulgel 600, SIMULGEL INS 100, etc.; anionic emulsifiers, such as magnesium stearate, sodium dodecylbenzene sulfonate, etc., which can be one or more of these, preferably SIMULGEL INS 100. 100 refers to commercially available products, including hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, isohexadecane, polysorbate-60, water, and sorbitan isostearate. In some specific implementations, the content of the emulsifier is preferably 0.05wt% to 3wt%, more preferably 0.1wt% to 1wt%.

[0240] In this application, the pH adjuster is used to neutralize the thickener system, allowing the cream to reach a suitable consistency. In some specific implementations, the pH adjuster includes, but is not limited to, alkanolamine pH adjusters, such as aminomethylpropanol complexes, triethanolamine, diethanolamine, and monoethanolamine; and organic acid and salt pH adjusters, such as citric acid and sodium citrate, lactic acid and sodium lactate, malic acid, etc., and may be one or more of these, preferably an aminomethylpropanol complex comprising 95% aminomethylpropanol and 9% water. In some specific implementations, the content of the pH adjuster is preferably 0.005wt%~0.5wt%, more preferably 0.01wt%~0.1wt%.

[0241] In some specific implementations, the face mask includes:

[0242] 0.1wt%~15wt% of the B5 composition described in the above technical solution;

[0243] 0.1wt%~10wt% glycerol;

[0244] 0.001wt%~1wt% of acrylate / C10-30 alkanol acrylate crosspolymer;

[0245] 0.001wt%~1wt% xanthan gum;

[0246] 0.01wt%~5wt% of SIMULGEL INS 100;

[0247] 0.01wt%~5wt% squalane;

[0248] 0.001wt%~5wt% of p-hydroxyacetophenone;

[0249] 0.001wt%~5wt% of 1,3-butanediol;

[0250] 0.001wt%~5wt% of 1,2-hexanediol;

[0251] 0.001wt%~1wt% aminomethylpropanol complex;

[0252] And the remaining water.

[0253] In some specific implementations, the face mask includes:

[0254] 1wt%~10wt% of the B5 composition described in the above technical solution;

[0255] 1wt%~5wt% glycerol;

[0256] 0.01wt%~0.5wt% of acrylate / C10-30 alkanol acrylate crosspolymer;

[0257] 0.01wt%~0.5wt% xanthan gum;

[0258] 0.1wt%~1wt% SIMULGEL INS 100;

[0259] 0.05wt%~1wt% squalane;

[0260] 0.01wt%~1wt% of p-hydroxyacetophenone;

[0261] 0.01wt%~1wt% of 1,3-butanediol;

[0262] 0.01wt%~1wt% of 1,2-hexanediol;

[0263] 0.01wt%~0.5wt% of aminomethylpropanol complex;

[0264] And the remaining water.

[0265] In some specific implementations, the face mask includes:

[0266] 5.12 wt% of the B5 composition described in the above technical solution;

[0267] 5wt% glycerin;

[0268] 0.1 wt% of acrylate / C10-30 alkanol acrylate crosspolymer;

[0269] 0.1wt% xanthan gum;

[0270] 0.5wt% SIMULGEL INS 100;

[0271] 0.1 wt% squalane;

[0272] 0.5 wt% p-hydroxyacetophenone;

[0273] 1 wt% 1,3-Butanediol;

[0274] 0.5 wt% 1,2-hexanediol;

[0275] 0.1 wt% aminomethylpropanol compound;

[0276] And the remaining water.

[0277] This application combines hydrolyzed myrtle (Myrtus communis) leaf extract, panthenol, and carboxymethyl deacetylated chitosan to construct a three-stage sequential repair system of "energy repair - immune repair - regeneration repair." Specifically, hydrolyzed myrtle (Myrtus communis) leaf extract can target and activate the longevity protein SIRT-1, thereby enhancing mitochondrial activity and cellular energy (ATP) production. Panthenol has multiple beneficial skincare effects, including repairing the skin barrier, reducing transepidermal water loss, relieving skin redness, burning and stinging, and strengthening the stratum corneum. Carboxymethyl deacetylated chitosan possesses both good film-forming density and moderate biological activity, achieving a synergistic effect between physical barrier function and biological repair. The combined use of these three components has a synergistic effect in reducing the expression of inflammatory factors, increasing IVL and LOR expression, and promoting type I collagen secretion. It has soothing, repairing, anti-aging, and skin redness and transepidermal water loss improvement effects, as well as repairing skin damaged after cosmetic procedures and repairing skin with a damaged barrier. Attached Figure Description

[0278] Figure 1 This is a fluorescence imaging diagram of mitochondrial membrane potential changes in an embodiment of this application;

[0279] Figure 2 This is a bar chart showing the elevation of mitochondrial membrane potential in an embodiment of this application;

[0280] Figure 3 Bar chart showing the inhibition of IL-8 inflammatory factor mRNA by the compositions provided in Example 1 and the comparative examples of this application;

[0281] Figure 4Bar chart showing the inhibition of IL-8 inflammatory factor mRNA by the compositions provided in Example 2 and the comparative examples of this application;

[0282] Figure 5 This is a bar chart showing the expression of IVL inner lining protein mRNA in Example 1 and the comparative example of this application;

[0283] Figure 6 This is a bar chart showing the expression of IVL inner lining protein mRNA in Example 2 and the comparative example of this application;

[0284] Figure 7 This is a bar chart showing the expression of LOR beak protein mRNA in Example 1 and the comparative example of this application;

[0285] Figure 8 This is a bar chart showing the expression of LOR beak protein mRNA in Example 2 and the comparative example of this application;

[0286] Figure 9 This is a bar chart showing the expression of type I collagen mRNA in the test examples of this application;

[0287] Figure 10 These are example images illustrating the human body's ability to soothe and improve redness in the test cases of this application.

[0288] Figure 11 The images are examples of human dermal thickness improvement in the test cases of this application. Detailed Implementation

[0289] This invention provides a B5 composition with barrier-thickening and repairing effects, and its application in cosmetics. Those skilled in the art can refer to this document and appropriately modify the process parameters to achieve the desired result. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to realize and apply the technology of this invention.

[0290] The terms “including,” “having,” or “containing,” including the use of their grammatical synonyms, should generally be understood as open-ended and non-restrictive, for example, not excluding other unstated elements or steps, unless otherwise specifically stated or understood from the context.

[0291] It should be understood that the order of the steps or the order in which certain actions are performed is not important as long as the invention remains operational. Furthermore, two or more steps or actions can be performed simultaneously.

[0292] The use of any and all instances or exemplary language such as “e.g.” or “including” in this document is merely intended to better illustrate the invention and is not intended to limit the scope of the invention unless the claims are made. No language in this specification should be construed as indicating that any unclaimed element is essential to the practice of the invention.

[0293] Furthermore, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Therefore, unless explicitly stated otherwise, it should be understood that all ranges, quantities, values, and percentages used in this disclosure are modified with the word "approximately". Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a specific value or range.

[0294] This application provides a B5 composition with barrier-thickening and repairing effects, comprising: hydrolyzed myrtle leaf extract, panthenol, and carboxymethyl deacetylated chitosan;

[0295] The mass ratio of the hydrolyzed myrtle leaf extract raw material, panthenol, and carboxymethyl deacetylated chitosan is 0.001~5:0.2~10:0.001~0.5.

[0296] This application combines hydrolyzed myrtle (Myrtus communis) leaf extract, panthenol, and carboxymethyl deacetylated chitosan to construct a three-stage sequential repair system of "energy repair - immune repair - regeneration repair." Specifically, the hydrolyzed myrtle (Myrtus communis) leaf extract can target and activate the longevity protein SIRT-1, thereby enhancing mitochondrial activity and cellular energy (ATP) production. Panthenol has multiple beneficial skincare effects, including repairing the skin barrier, reducing transepidermal water loss, relieving skin redness, burning and stinging, and strengthening the stratum corneum. Carboxymethyl deacetylated chitosan possesses both good film-forming density and moderate biological activity, achieving a synergistic effect between physical barrier function and biological repair. The combined use of these three components has a synergistic effect in reducing inflammatory factor expression, increasing IVL and LOR expression, and promoting type I collagen secretion. It has soothing, repairing, anti-aging, and skin redness and transepidermal water loss improvement effects, as well as repairing skin damaged after cosmetic procedures and repairing skin with a damaged barrier.

[0297] The present invention also provides a product comprising: the B5 composition described in the above technical solution.

[0298] Specifically, the products provided in this application include, but are not limited to, soothing and repairing toners, soothing and repairing lotions, soothing and repairing creams, soothing and repairing serums, soothing and repairing gels, and soothing and repairing masks. In some specific implementations, the products include 0.1wt% to 10wt% of the B5 composition described in the above-mentioned technical solutions, preferably 0.5wt% to 9.5wt% of the B5 composition described in the above-mentioned technical solutions, and more preferably 1wt% to 9wt% of the B5 composition described in the above-mentioned technical solutions.

[0299] The product provided in this application synergistically reduces inflammation, enhances cellular energy, promotes regeneration, and improves skin stress. It is a comprehensive, time-series repair composition covering the entire "energy repair - immune repair - regenerative repair" chain, enabling deeper skin barrier reconstruction and targeted anti-aging enhancement. The product not only has significant synergistic soothing and repairing effects but also effectively alleviates sensitivity symptoms in sensitive skin and facilitates rapid repair after cosmetic procedures. Experimental results show that the B5 composition provided in this application has a synergistic coefficient q of 1.32 in IL-8 inhibition, 34.2 in promoting IVL expression, 1.80 in promoting LOR expression, and 2.05 in promoting type I collagen production, indicating that the B5 composition provided in this application has a synergistic effect in soothing repair and anti-aging. Moreover, the B5 composition provided in this application exhibits significant soothing, repairing, firming, and elasticity effects in both human scenarios, including daily use on sensitive skin and post-medical aesthetic repair. It is also gentle and non-irritating, suitable for care of skin with damaged skin barriers and in highly sensitive conditions, and has broad application prospects.

[0300] The following examples further illustrate the B5 composition with barrier-strengthening and repairing effects provided in this application.

[0301] In the following embodiments, the hydrolyzed myrtle (Myrtus communis) leaf extract, panthenol, carboxymethyl deacetylated chitosan, centella asiatica leaf extract, and sodium hyaluronate are all commercially available products. The hydrolyzed myrtle (Myrtus communis) leaf extract comprises 3.5 wt% hydrolyzed myrtle (Myrtus communis) leaf extract, 10 wt% 1,2-pentanediol, and the balance being water.

[0302] The raw material for Centella asiatica leaf extract includes 10 wt% Centella asiatica leaf extract, 0.5 wt% 1,2-hexanediol, 0.4 wt% p-hydroxyacetophenone and the balance water;

[0303] The panthenol is D-panthenol, CAS number 81-13-0;

[0304] The CAS number of the carboxymethyl deacetylated chitosan is 83512-85-0, and the number average molecular weight is 300,000 Da;

[0305] The sodium hyaluronate has a CAS number of 9067-32-7 and a number-average molecular weight of 200,000 to 400,000 Da.

[0306] Examples 1-2, Comparative Examples 1-6

[0307] According to the formula shown in Table 1, the raw materials are mixed to obtain the composition.

[0308] Table 1. Mass percentages of the compositions provided in the embodiments and comparative examples of this application.

[0309]

[0310] Test Example 1: Activation of cellular energy metabolism (mitochondrial membrane potential detection)

[0311] Experimental Objective: After skin damage or cosmetic treatment, keratinocytes and fibroblasts are in a state of high stress and energy consumption, urgently requiring exogenous energy support. Therefore, timely restoration of mitochondrial function and replenishment of cellular energy reserves are core prerequisites for initiating and maintaining an efficient repair process. The composition provided in this application focuses on enhancing mitochondrial membrane potential, thereby activating cellular energy metabolism. Mitochondrial membrane potential (MMP) is a core indicator for evaluating mitochondrial functional status, directly reflecting the coupling efficiency of the electron transport chain and ATP synthesis capacity. This test case uses human foreskin fibroblasts (HFF) as a model, employing the JC-1 fluorescent probe to detect changes in mitochondrial membrane potential after composition treatment. JC-1 emits red fluorescence in the form of aggregates when the mitochondrial membrane potential is high, and green fluorescence in the form of monomers when the membrane potential is low. A higher red / green fluorescence ratio indicates a higher mitochondrial membrane potential and more active energy metabolism. This test case evaluates the activating effect of the composition on cellular energy metabolism, providing a foundational basis for the subsequent full-time repair logic of "strengthening the energy base—anti-inflammatory soothing—barrier repair—collagen regeneration".

[0312] Experimental methods:

[0313] 1.1 Cell Culture

[0314] Human foreskin fibroblasts (HFF, passage 8) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator until 70%–80% confluence. Cells were harvested from the monolayer culture and seeded into confocal dishes at a density of 1.5 × 10⁶ cells / mL. 4 Cells / well. After culturing for 6 hours to allow cells to adhere, pretreat the cells with serum-free medium for 18 hours.

[0315] The detailed test plan is shown in Table 2, which is the detailed test plan for Test Example 1.

[0316] Table 2 Detailed Test Plan for Test Example 1

[0317]

[0318] 1.2 Administration

[0319] According to the test groups, when the cell confluence rate in the confocal dish reached 50%–70%, the drugs were administered to the groups, with three replicates per group. 300 μL of culture medium was added to each well of the blank control group and negative control group, 300 μL of 100 ng / ml TGF-β was added to each well of the positive control group, and 300 μL of culture medium containing the corresponding test sample was added to each well of the sample group. Except for the blank control, all other groups were stimulated with 5 μg / mL LPS. After drug administration, the confocal dishes were placed in an incubator (conditions: 37℃, 5% CO2) for 24 h.

[0320] 1.3 Probe Loading

[0321] 1.3.1 JC-1 probe loading

[0322] The JC-1 probe was loaded using Invitrogen mitochondrial membrane potential dye, following the manufacturer's instructions. The JC-1 probe was diluted 1:200 with PBS to obtain a working solution of JC-1 with a final concentration of 10 μg / mL. The cell culture medium was removed, and 300 μL of the diluted JC-1 was added. The cells were incubated at 37°C for 20 minutes. The cells were washed three times with PBS to thoroughly remove any uncontaminated JC-1.

[0323] 1.3.2 Hoechst probe loading

[0324] Live cell nuclei were labeled using the MCE Hoechst 33342 analog probe, following the manufacturer's instructions. The Hoechst probe was diluted 1:200 with PBS to obtain a working solution with a final concentration of 5 μg / mL. The cell culture medium was removed, and 300 μL of the diluted Hoechst working solution was added. The cells were incubated at 37°C for 10 minutes. The cells were washed twice with PBS to thoroughly remove any Hoechst that had not yet entered the cells.

[0325] 1.3.3 Fluorescence Detection

[0326] The samples were directly observed using a laser confocal microscope. The excitation wavelength of the JC-1 monomer was 490 nm, and the emission wavelength was 530 nm. The excitation wavelength of the JC-1 polymer was 525 nm, and the emission wavelength was 590 nm. The excitation wavelength of Hoechst after binding to the DNA double strand was 356 nm, and the emission wavelength was 451 nm.

[0327] 1.4 Statistical Analysis of Results

[0328] Mean fluorescence intensities of red, green, and blue fluorescence were calculated using ImageJ software. GraphPad Prism was used for plotting, and results are expressed as Mean ± SD. One-way ANOVA was used for comparisons between groups. Blank control (BC) vs. negative control (NC): significance is expressed as... # Indicates: Sample group vs. negative control (NC): significance is expressed as... * express, * :p<0.05, ** :p<0.01, *** :p<0.001.

[0329] 1.5 Experimental Results

[0330] See results Figure 1 , Figure 2 And Table 3, Figure 1 This is a fluorescence imaging diagram of mitochondrial membrane potential changes in an embodiment of this application; Figure 2 Table 3 shows the bar chart of mitochondrial membrane potential enhancement in an embodiment of the present invention; Table 3 shows the efficacy test results of the composition provided in this application in enhancing mitochondrial activity in human foreskin fibroblasts.

[0331] Table 3. Results of efficacy testing of the composition provided in this application in enhancing mitochondrial activity in human foreskin fibroblasts.

[0332]

[0333] Depend on Figure 1 , Figure 2 As shown in Table 3:

[0334] Compared with the BC group, the JC-1 aggregate / monomer fluorescence intensity ratio was reduced in the NC group, and the mitochondrial membrane potential was significantly decreased, indicating that the stimulation conditions in this test were effective.

[0335] Compared with the NC group, the PC group showed an increased JC-1 aggregate / monomer fluorescence intensity ratio and a significantly enhanced mitochondrial membrane potential, proving that the model was successfully established in this experiment.

[0336] Compared with the NC group, the sample group (Example 1) showed an increased JC-1 aggregate / monomer fluorescence intensity ratio and a significantly increased mitochondrial membrane potential, with an increase rate of 32.31%. The results indicate that this composition has the effect of activating mitochondrial activity, thereby having a stronger repair and regeneration capacity.

[0337] Conclusion: The composition provided in this application first plays a core regulatory role at the level of cellular energy metabolism. It can significantly increase mitochondrial membrane potential (JC-1 aggregate / monomer fluorescence intensity ratio increased by 32.31%), activate mitochondrial activity, enhance cellular ATP production capacity, and thus comprehensively improve the energy supply and self-repair potential of damaged cells.

[0338] Test Example 2: Validation of Synergistic Anti-inflammatory, Soothing, and Redness-Reducing Efficacy (IL-8 Pro-inflammatory Factor Inhibition Detection)

[0339] Experimental Objective: After skin is stimulated by external factors or undergoes cosmetic treatments, the damaged area rapidly initiates an inflammatory response—keratinocytes release large amounts of chemokines such as IL-8, which not only recruits immune cells to abnormally infiltrate and exacerbate tissue damage but also indirectly promotes local vasodilation, manifesting as discomfort symptoms such as skin redness, burning, and stinging. If the inflammation is not promptly resolved, the repair window will be delayed, hindering subsequent barrier reconstruction and collagen regeneration. Therefore, with a solid energy foundation in place, rapid extinguishing of the inflammation is a crucial intermediate step connecting energy activation and tissue repair. This test focuses on verifying whether the composition of this application can effectively and moderately inhibit the release of the key pro-inflammatory factor IL-8 through synergistic formulation, thereby achieving rapid soothing and redness-reducing effects.

[0340] Experimental methods:

[0341] 2.1 Cell Culture

[0342] Human keratinocytes (HaCaT, passage 18) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator until they reached 50%–70% confluence. The cells were then harvested and seeded into 12-well plates at a density of 1.5 × 10⁶ cells / well. 5 Cells were cultured in wells for 6 hours until they adhered, then pretreated with serum-free medium for 18 hours.

[0343] The detailed test plan is shown in Table 4, which is the detailed test plan for Test Example 2.

[0344] Table 4 Detailed Test Plan for Test Case 2

[0345]

[0346]

[0347] 2.2 Administration

[0348] According to the test groups, when the cell deposition rate in the 12-well plates reached 50%–70%, the drugs were administered to the groups, with three replicates per group. 1 mL of culture medium was added to each well of the blank control group and negative control group, 1 mL of 100 ng / mL TGF-β was added to each well of the positive control group, and 1 mL of culture medium containing the corresponding test sample was added to each well of the sample group. Except for the blank control group, all other groups were stimulated with 5 μg / mL LPS. After drug administration, the 12-well plates were placed in an incubator (conditions: 37℃, 5% CO2) for 24 h.

[0349] 2.3 RNA extraction and q-PCR

[0350] RNA extraction: Total RNA was extracted from each group of cells using the Tiangen Total RNA Extraction Kit, following the instructions. RNA concentration and purity were measured using a spectrophotometer to ensure an OD260 / OD280 ratio between 1.8 and 2.0.

[0351] Reverse transcription: Take 1 μg of total RNA and use TOYOBO's ReverTra Ace™ qPCR RT Master Mix for reverse transcription to synthesize cDNA.

[0352] q-PCR: Using cDNA as a template, q-PCR was performed on a real-time quantitative PCR instrument using SYBR™ Green Realtime PCR Master Mix. The reaction volume was 20 μL, including 10 μL SYBR™ Green Realtime PCR Master Mix, 0.8 μL upstream primer, 0.8 μL downstream primer, 2 μL cDNA template, and 6.4 μL ddH2O. The reaction conditions were: 95℃ pre-denaturation for 30 seconds; 95℃ denaturation for 5 seconds, 60℃ annealing for 30 seconds, for a total of 40 cycles. GAPDH was used as an internal reference gene, and the relative expression level of the gene was calculated using the 2^-ΔΔCt method. Detailed PCR test parameters are shown in Table 5, which contains detailed parameters for the IL-8 anti-inflammatory gene PCR test.

[0353] Table 5 Detailed parameters for IL-8 anti-inflammatory gene PCR assay

[0354]

[0355] 2.4 Statistical Analysis of Results

[0356] GraphPad Prism was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for statistical analysis to compare the groups. Blank control (BC) vs. negative control (NC): significance is expressed as...# Indicates: Sample group vs. negative control (NC): significance is expressed as... * express, * :p<0.05, ** :p<0.01, *** :p<0.001.

[0357] 2.5 Due to the limited number of samples available in each batch, this study was conducted in two batches: the first batch consisted of Example 1 versus Comparative Examples 1-4, and the second batch consisted of Example 2 versus Comparative Examples 5-6. See the attached table for experimental results. Figure 3 , Figure 4 Tables 6 and 7, Figure 3 The bar chart shows the inhibition of IL-8 inflammatory factor mRNA by the compositions provided in Example 1 and the comparative examples of this application. Figure 4 Table 6 shows the bar chart of the inhibition of IL-8 inflammatory factor mRNA by the compositions provided in Example 2 and the comparative examples of this application. Table 7 shows the results of the efficacy test of the compositions provided in Example 1 and the comparative examples of this application in inhibiting inflammatory factors in Hacat cells.

[0358] Table 6. Results of efficacy testing of Example 1 and comparative examples in inhibiting inflammatory factors in Hacat cells provided in this application.

[0359]

[0360] Table 7. Results of efficacy testing of Example 2 and the comparative example in inhibiting inflammatory factors in Hacat cells.

[0361]

[0362] Depend on Figure 3 , Figure 4 From Tables 6 and 7, we can see that:

[0363] Compared with the NC group, the compositions provided in Examples 1 and 2 of this application significantly reduced the expression level of the IL-8 inflammatory factor, and according to the synergy calculation formula q=E A+B / (E A +E B -E A ×E B Calculations showed that the synergistic coefficient q of Example 1 relative to Comparative Examples 1 and 2 was 1.32, and the synergistic coefficient q of Example 2 relative to Comparative Examples 5 and 6 was 1. This indicates that at the tested concentration, the combination of panthenol, carboxymethyl deacetylated chitosan, and hydrolyzed myrtle extract disclosed in Example 1 produced a synergistic effect.

[0364] The composition provided in this application inhibits IL-8 overexpression, preventing abnormal chemotaxis and infiltration of immune cells. While effectively blocking tissue damage caused by excessive immune responses, it preserves normal immune surveillance function. As in Test Example 1, the composition first strengthens the cell's energy base by increasing mitochondrial membrane potential (JC-1 ratio increased by 32.31%). Sufficient ATP supply makes keratinocytes more resilient to inflammatory signals under stress, thereby efficiently regulating the excessive release of IL-8 and promptly calming the inflammatory environment. Clinically, this manifests as a significant reduction in skin redness and a marked relief of burning and stinging discomfort. Rapid resolution of inflammation means an earlier opening of the repair window, allowing damaged cells to transition from a defensive state to a repair mode as soon as possible, orderly promoting barrier structure reconstruction.

[0365] Test Example 3: Epidermal Layer Reconstruction - Synergistic Reconstruction of Epidermal Barrier Function (Detection of IVL and LOR Barrier Protein mRNA Expression)

[0366] Experimental Objective: The keratinized capsule (CE) is the foundation of the skin barrier structure. Damage to the CE leads to increased transepidermal water loss (TEWL) and exacerbated inflammation due to irritant penetration. This test case aims to verify whether the composition can synergistically promote the expression of key CE proteins—inner lamina protein IVL and the main component, lobe protein LOR (accounting for >70% of CE protein). Combined with increased energy (JC-1 ratio increased by 32.31%), sufficient ATP provides energy for the synthesis and cross-linking of these proteins, driving CE construction. Clinically, this resulted in a significant improvement in TEWL, confirming effective barrier reconstruction.

[0367] 3.1 Cell Culture

[0368] Human keratinocytes (HaCaT, passage 18) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator until they reached 50%–70% confluence. The cells were then harvested and seeded into 12-well plates at a density of 1.5 × 10⁶ cells / well. 5 Cells / well. After culturing for 6 hours to allow cells to adhere, pretreat the cells with serum-free medium for 18 hours.

[0369] 3.2 Administration

[0370] According to the test groups shown in Table 4, when the cell deposition rate in the 12-well plates reached 50%–70%, the drugs were administered to the groups, with three replicates per group. 1 mL of culture medium was added to each well of the blank control group and negative control group, 1 mL of 100 ng / mL TGF-β was added to each well of the positive control group, and 1 mL of culture medium containing the corresponding test sample was added to each well of the sample group. Except for the blank group, all other groups were stimulated with 5 μg / mL LPS. After drug administration, the 12-well plates were incubated in an incubator (conditions: 37℃, 5% CO2) for 24 h.

[0371] 3.3 RNA extraction and q-PCR

[0372] RNA extraction: Total RNA was extracted from each group of cells using the Tiangen Total RNA Extraction Kit, following the instructions. RNA concentration and purity were measured using a spectrophotometer to ensure an OD260 / OD280 ratio between 1.8 and 2.0.

[0373] Reverse transcription: Take 1 μg of total RNA and use TOYOBO's ReverTra Ace™ qPCR RT Master Mix for reverse transcription to synthesize cDNA.

[0374] q-PCR: Using cDNA as a template, q-PCR was performed on a real-time quantitative PCR instrument using SYBR™ Green Realtime PCR Master Mix. The reaction volume was 20 μL, including 10 μL SYBR™ Green Realtime PCR Master Mix, 0.8 μL upstream primer, 0.8 μL downstream primer, 2 μL cDNA template, and 6.4 μL ddH2O. The reaction conditions were: 95℃ pre-denaturation for 30 seconds; 95℃ denaturation for 5 seconds, 60℃ annealing for 30 seconds, for a total of 40 cycles. GAPDH was used as an internal reference gene, and the relative expression level of the gene was calculated using the 2^-ΔΔCt method. Detailed information is shown in Table 8 below, which contains detailed parameters for the PCR test of the barrier protein gene in Test Example 3.

[0375] Table 8 Detailed parameters for PCR test of barrier protein gene in Test Example 3

[0376]

[0377] 3.4 Statistical Analysis of Results

[0378] GraphPad Prism was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for statistical analysis to compare the groups. Blank control (BC) vs. negative control (NC): significance is expressed as... # Indicates: Sample group vs. negative control (NC): significance is expressed as... * express, * :p<0.05, ** :p<0.01, *** :p<0.001.

[0379] 3.5 Experimental Results

[0380] Due to the limited number of samples available in each batch, this study was conducted in two batches: the first batch consisted of Example 1 versus Comparative Examples 1–4, and the second batch consisted of Example 2 versus Comparative Examples 5–6. Results are shown below. Figure 5 , Figure 6 , Figure 7 , Figure 8 Tables 9, 10, 11, and 12 Figure 5 This is a bar chart showing the expression of IVL barrier protein mRNA in Example 1 and the comparative example of this application. Figure 6 This is a bar chart showing the expression of IVL barrier protein mRNA in Example 2 and the comparative example of this application. Figure 7 This is a bar chart showing the expression of LOR barrier protein mRNA in Example 1 and the comparative example of this application. Figure 8 Table 9 shows the effect of Example 1 and the comparative example on the expression of LOR barrier protein mRNA in Hacat cells. Table 10 shows the effect of Example 2 and the comparative example on the expression of IVL barrier-related protein mRNA in Hacat cells. Table 11 shows the effect of Example 1 and the comparative example on the expression of LOR barrier-related protein mRNA in Hacat cells. Table 12 shows the effect of Example 2 and the comparative example on the expression of LOR barrier-related protein mRNA in Hacat cells.

[0381] Table 9. Results of the effects of Example 1 and comparative examples on the mRNA expression of IVL barrier-related proteins in Hacat cells.

[0382]

[0383] Table 10 Results of the effects of Example 2 and the comparative examples on the mRNA expression of IVL barrier-related proteins in Hacat cells

[0384]

[0385] Table 11 Results of the effects of Example 1 and comparative examples on the mRNA expression of LOR barrier-related proteins in Hacat cells

[0386]

[0387] Table 12 Results of the effects of Example 2 and comparative examples on the mRNA expression of LOR barrier-related proteins in Hacat cells

[0388]

[0389] From Tables 9, 10, 11, and 12, Figure 5 , Figure 6 , Figure 7 and Figure 8 It can be known that:

[0390] Compared to the NC group, the composition provided in this application significantly increases the expression levels of two barrier proteins, specifically targeting IVL barrier-related protein mRNA expression, according to the synergy calculation formula q=E. A+B / (E A +E B -E A ×E B Calculations were performed, and for Example 1 relative to Comparative Examples 1 and 2, q = 34.2; for Example 2 relative to Comparative Examples 5 and 6, q = 1.57. Regarding the expression of LOR barrier-related protein mRNA, the cooperability calculation formula q = E was used. A+B / (E A +E B -E A ×E B Calculations show that, in Example 2, q = 1.80 compared to Comparative Examples 5 and 6. Therefore, the combination of panthenol, carboxymethyl deacetylated chitosan, and hydrolyzed myrtle extract produced a synergistic effect.

[0391] The composition provided in this application can significantly promote the expression of IVL and LOR barrier proteins, which are the scaffold and main structural components of the keratinized capsule, respectively. Combined with increased mitochondrial energy (JC-1 ratio increased by 32.31%), it provides ATP support for protein synthesis and cross-linking assembly, thereby forming a dense keratinized capsule, ultimately manifested as a significant improvement in TEWL value, confirming substantial repair of barrier function.

[0392] Test Example 4: Dermal Regeneration—Synergistic Promotion of Type I Protein Secretion

[0393] Experimental Objective: Type I collagen (Col I) accounts for 80%–90% of total skin collagen and is a key structural component of the dermal matrix, directly determining skin firmness and elasticity. After skin damage or cosmetic procedures, fibroblasts' ability to synthesize collagen decreases, while increased MMP activity under inflammatory conditions exacerbates collagen degradation, leading to a loosening of the dermal matrix and wrinkle formation. Therefore, based on the aforementioned energy activation, inflammation reduction, and barrier reconstruction, further promoting Col I regeneration is the final closed loop for comprehensive repair. This test case verifies whether panthenol, carboxymethyl deacetylated chitosan, and hydrolyzed myrtle extract can synergistically promote the secretion of Col I by dermal fibroblasts (HDF). Combined with an increase in mitochondrial membrane potential (JC-1 ratio increased by 32.31%), sufficient ATP provides energy support for the energy-consuming processes of Col I transcription, translation, and hydroxylation, synergistically stimulating fibroblast vitality and efficiently driving Col I regeneration, clinically manifested as improved skin firmness, reduced wrinkles, and improved facial contours. This completes the full-level repair loop of "energy activation - anti-inflammatory and soothing - barrier reconstruction - dermal collagen regeneration".

[0394] 4.1 Cell Culture

[0395] Human fibroblasts (HDF, passage 8) were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator until they reached 50%–70% confluence. The cells were then seeded into 12-well plates at a density of 1.5 × 10⁶ cells / well. 5 Cells / well. After culturing for 6 hours to allow cells to adhere, pretreat the cells with serum-free medium for 18 hours.

[0396] 4.2 Administration

[0397] According to the test groups shown in Table 4, when the cell deposition rate in the 12-well plates reached 50%–70%, modeling was performed, and drugs were administered to the affected groups, with three replicates per group. Except for the blank control, all other groups were subjected to 15 J / cm² treatment. 2 After UVA stimulation, 1 mL of culture medium was added to each well of the negative control group, 1 mL of 100 ng / mL TGF-β was added to each well of the positive control group, and 1 mL of culture medium containing the corresponding test sample was added to each well of the sample group. After drug administration, the 12-well plate was placed in an incubator (conditions: 37℃, 5% CO2) and cultured for 24 h.

[0398] 4.3 RNA extraction and qPCR

[0399] RNA extraction: Total RNA was extracted from each group of cells using the Tiangen Total RNA Extraction Kit, following the instructions. RNA concentration and purity were measured using a spectrophotometer to ensure an OD260 / OD280 ratio between 1.8 and 2.0.

[0400] Reverse transcription: Take 1 μg of total RNA and use TOYOBO's ReverTra Ace™ qPCR RT Master Mix for reverse transcription to synthesize cDNA.

[0401] qPCR: Using cDNA as a template, qPCR was performed on a real-time quantitative PCR instrument using SYBR™ Green Realtime PCR Master Mix. The reaction volume was 20 μL, including 10 μL SYBR™ Green Realtime PCR Master Mix, 0.8 μL upstream primer, 0.8 μL downstream primer, 2 μL cDNA template, and 6.4 μL ddH2O. The reaction conditions were: 95℃ pre-denaturation for 30 seconds; 95℃ denaturation for 5 seconds, 60℃ annealing for 30 seconds, for a total of 40 cycles. GAPDH was used as an internal reference gene, and the relative expression level of the gene was calculated using the 2^-ΔΔCt method. Specific test information is shown in Table 13 below:

[0402] Table 13 Detailed parameters for Col I A1 gene PCR test

[0403]

[0404] 4.4 Statistical Analysis of Results

[0405] GraphPad Prism was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for comparisons between groups. Blank control (BC) vs. negative control (NC): significance is expressed as... # Indicates: Sample group vs. negative control (NC): significance is expressed as... * express, * :p<0.05, ** :p<0.01, *** :p<0.001.

[0406] 4.5 Experimental Results

[0407] See results Figure 9 And Table 14, Figure 9 The bar chart shows the expression of type I collagen mRNA in the test examples of this application. Table 14 shows the effect of the composition on the secretion of type I collagen in HDF cells.

[0408] Table 14 Results of the effect of the composition on the secretion of type I collagen in HDF cells

[0409]

[0410] Depend on Figure 9 As shown in Table 14:

[0411] Collagen is the core framework of the dermal matrix, with type I collagen (Col I) accounting for 80%–90% of the total collagen in the skin and closely related to skin softness, elasticity, and repair capabilities. The composition provided in this application significantly promotes Col I synthesis, and its promoting effect (Example 1) exceeds the absolute value of the sum of the effects of each individual component (panthenol, carboxymethyl deacetylated chitosan, and hydrolyzed myrtle extract). According to the synergistic calculation formula q=E... A+B / (E A +E B EA × EB ) Calculations show that, relative to Comparative Examples 1 and 2, q = 2.05 (q > 1) in Example 1, which fully demonstrates that the combination of the three components produced a synergistic effect.

[0412] Combined with the aforementioned significant increase in mitochondrial membrane potential (JC-1 ratio increased by 32.31%), ample ATP supply provides sufficient energy support for the transcription, translation, and post-translational modifications such as proline / lysine hydroxylation of Col I within fibroblasts. Collagen, as a long-chain triple-helix protein, undergoes highly energy-intensive synthesis and secretion; activation of energy metabolism is a crucial prerequisite for efficient collagen regeneration. Building upon the aforementioned "energy activation—inflammation reduction—barrier reconstruction," the composition provided in this application further penetrates the dermis, stimulating fibroblast vitality and efficiently driving the synergistic regeneration of Col I, achieving full-layer coverage from epidermal soothing to dermal regeneration. In human clinical settings, sufficient synthesis and orderly deposition of Col I directly manifest as improved skin firmness, reduced wrinkles, and improved facial contours, confirming that the composition provided in this application, in addition to anti-inflammatory soothing and barrier repair, also possesses clear synergistic anti-aging and revitalizing effects.

[0413] Test Example 5: Formulations Applicable to Different Cosmetic Dosage Forms

[0414] This test example is a non-limiting embodiment of the composition of the present invention. The examples are given for illustrative purposes only and should not be construed as limiting the invention, as many modifications are possible without departing from the spirit and scope of the invention, as will be appreciated by those skilled in the art. In the examples, unless otherwise specified, all concentrations are listed as weight percentages, and minor substances such as diluents, fillers, etc., are excluded. Therefore, the listed formulations include the listed components and any minor substances associated with those components. It will be apparent to those skilled in the art that the selection of these minor components will vary depending on the physical and chemical properties of the specific ingredients chosen to manufacture the invention described herein. The compositions of the present invention are widely applicable to various cosmetic dosage forms, including but not limited to: soothing and repairing toners, soothing and repairing lotions, soothing and repairing creams, soothing and repairing serums, soothing and repairing gels, and soothing and repairing masks, etc.

[0415] Toners, lotions, and creams were prepared using the formulas shown in Tables 15-17 using traditional methods.

[0416] Table 15 Soothing and Repairing Toner Formula

[0417]

[0418] Table 16 Soothing and Repairing Lotion Formula

[0419]

[0420] In Table 16, MONTANOV 202 emulsifier is a commercially available product, including: arachidonic acid, behenyl alcohol, arachidonic acid glucoside, water, and glucose;

[0421] SEPIGEL 30 emulsifiers are commercially available products and include: polyacrylamide, C13-14 isoparaffins, and lauryl ether-7.

[0422] Table 17 Soothing and Repairing Face Cream Formula

[0423]

[0424] Test Example 6: Human Efficacy Verification—Soothing, Repairing, Firming and Elasticity (Dual Dimensions: Sensitive Skin and Post-Medical Aesthetic Treatment)

[0425] Test Objective: The aforementioned test examples 1-4 systematically verified the synergistic repair mechanism of the composition provided in this application at the in vitro level from four dimensions: activation of cellular energy metabolism, inhibition of the inflammatory factor IL-8, upregulation of epidermal barrier protein IVL / LOR expression, and dermal Col I collagen regeneration. To further verify the safety and efficacy of the composition provided in this application on actual human skin, this test example conducts an efficacy evaluation at the human level. Following the formulation shown in Table 18, a facial mask was prepared using traditional methods, and human efficacy verification was carried out, with demonstrations conducted for two typical application scenarios.

[0426] Table 18 Soothing Mask Formula

[0427]

[0428] In Table 18, SIMULGEL INS 100 emulsifier is a commercially available product, including: hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, isohexadecane, polysorbate-60, water, and sorbitan isostearate.

[0429] Human efficacy verification 1: Certification for soothing, repairing and improving skin for sensitive individuals

[0430] 6.1.1 Test Plan

[0431] Thirty-two subjects with sensitive skin used the sample continuously for 7 days. The results were evaluated by comparing the before and after results using instrumental testing, clinical assessment, and subjective questionnaire assessment. The effects of the test sample on soothing, repairing, firming, gentleness (non-irritating), efficacy for sensitive skin, and improving dermal thickness, dermal density, epidermal thickness, epidermal density, and relieving stinging were assessed.

[0432] 6.1.2 Test parameters and instruments:

[0433] ① Soothing effect: The testing instrument uses VISIA-CRIPP analysis to monitor the difference and rate of change in skin redness a* value and the proportion of red area between the face before use (D0) and after 7 days of continuous product use (D7). The smaller the parameter value, the less red the skin color.

[0434] ② Barrier repair efficacy: The testing instrument uses Tewameter to analyze and monitor the difference in transepidermal water loss rate between the face before use (D0) and after 7 days of continuous product use (D7). The smaller the parameter value, the less transepidermal water loss.

[0435] ③Effects to enhance epidermal density and thickness: The testing instrument uses DermaScan C analysis to monitor the changes in epidermal density and thickness before application (D0) and after 7 days of continuous product use (D7). The higher the parameter value, the greater the epidermal thickness and density.

[0436] ④ Enhances dermal density and thickness: The testing instrument uses DermaScan C to analyze and monitor the changes in dermal density and thickness on the face before use (D0) and after 7 days of continuous product use (D7). The larger the parameter value, the greater the dermal thickness and density.

[0437] 6.1.3 Data Statistical Analysis Methods

[0438] The software was used to perform descriptive statistics on the measured values ​​at each test time point, including the mean and standard error.

[0439] For quantitative data: First, the Shapiro-Wilk Test was used to test the normality of the data changes. If the data were normally distributed, a paired-samples t-test was used; otherwise, a Wilcoxon rank-sum test was used for two related samples. The significance level was set at α = 0.05.

[0440] Ordinal data: The comparison before and after use was performed using the Wilcoxon rank-sum test for two related samples, with a significance level of α=0.05.

[0441] Questionnaire data: The proportion of beneficial options (4 points + 5 points) was statistically analyzed, and a binomial distribution test was performed. The test proportion was 0.6, and the significance level α = 0.05. The degree of agreement was calculated as: (Number of people with beneficial options (4 points + 5 points) / Total number of people * 100%. Scoring criteria: 5 points for "Very satisfied / Very agree"; 4 points for "Satisfied / Agree"; 3 points for "Neutral"; 2 points for "Satisfied / Disagree"; 1 point for "Very dissatisfied / Very disagree".

[0442] Change rate % = (mean after use - mean before use) / mean before use * 100%.

[0443] 6.1.4 Test Results

[0444] See Figure 10 , Figure 11 And Table 19, Figure 10 These are example images illustrating the efficacy of this application in relieving redness and improving skin tone on the human body. Figure 11The images shown are examples of the improvement in dermal thickness in the human body in the test cases of this application. Table 19 summarizes the 7-day soothing and repairing effects of the soothing mask provided in this application.

[0445] Table 19 Summary of the 7-day soothing and repairing effects of the soothing mask provided in this application

[0446]

[0447] Figure 10 In the middle, the lighter the red, the less reddish it is; Figure 11 In the diagram, the more and brighter the bright portion, the greater the density of the dermis; the wider the white portion, the greater the thickness of the epidermis.

[0448] From Table 19, Figure 10 and Figure 11 It is evident that the facial mask provided in this application has clear soothing, repairing, and firming effects on the human body. After 7 days of continuous use, the subjects' skin redness significantly improved, and discomfort such as burning and stinging was significantly relieved; at the same time, the thickness of the dermis and epidermis significantly increased, indicating that the facial mask provided in this application can effectively promote the reconstruction of the epidermal barrier structure and the regeneration of the dermal matrix. The results of the consumer self-evaluation questionnaire showed that 100% of the subjects believed that their skin redness, stinging, and discomfort were improved after use, further corroborating the actual user experience of the facial mask. The above results corroborate the aforementioned three-dimensional in vitro mechanism (energy metabolism activation—inflammatory factor inhibition—synergistic promotion of barrier proteins and collagen), confirming that the facial mask provided in this application, through the synergistic combination of panthenol, carboxymethyl deacetylated chitosan, and hydrolyzed myrtle extract, achieves a closed-loop repair process at all levels, from cellular energy activation to epidermal barrier repair and then to dermal collagen regeneration.

[0449] Human Efficacy Verification 2: Immediate Soothing and Repairing Effects After Medical Aesthetic Procedures

[0450] 6.2.1 Test Plan

[0451] After a single use of the sample following a photon skin rejuvenation treatment, 33 participants underwent instrumental testing and subjective questionnaire evaluation. The results were compared before and after the treatment to assess the sample's effectiveness in immediate post-treatment repair and soothing.

[0452] 6.2.2 Test Indicators and Instruments

[0453] ① Soothing effect: The testing instrument uses Mexameter to analyze and monitor the change in skin hemoglobin content after the facial phototherapy treatment (D0) and 15 minutes after use (T15min). The smaller the parameter value, the lower the skin hemoglobin content.

[0454] ②Barrier repair efficacy: The testing instrument uses Tewameter to analyze and monitor the transepidermal water loss rate of the skin after phototherapy (D0) and 15 minutes after application (T15min). The smaller the parameter value, the less transepidermal water loss.

[0455] 6.2.3 Data Statistical Analysis Methods

[0456] The software was used to perform descriptive statistics on the measured values ​​at each test time point, including the mean and standard error.

[0457] For quantitative data: First, the Shapiro-Wilk Test was used to test the normality of the data changes. If the data were normally distributed, a paired-samples t-test was used; otherwise, a Wilcoxon rank-sum test was used for two related samples. The significance level was set at α = 0.05.

[0458] Questionnaire data: The proportion of beneficial options (4 points + 5 points) was statistically analyzed, and a binomial distribution test was performed. The test proportion was 0.6, and the significance level α = 0.05. The degree of agreement was calculated as: (Number of people with beneficial options (4 points + 5 points) / Total number of people * 100%. Scoring criteria: 5 points for "Very satisfied / Very agreeable"; 4 points for "Satisfied / Agreeable"; 3 points for "Neutral"; 2 points for "Dissatisfied / Disagreeable"; 1 point for "Very dissatisfied / Very disagreeable".

[0459] Change rate % = (Mean after use - Mean before use) / Mean before use * 100%

[0460] 6.2.4 Test Results

[0461] See Table 20, which summarizes the results of the immediate soothing and repair effects of the soothing mask provided in this application after medical aesthetic procedures.

[0462] Table 20 Summary of the immediate soothing and repairing effects of the soothing mask provided in this application after medical aesthetic procedures

[0463]

[0464] As shown in Tables 19 and 20, the facial mask provided in this application has both long-term improvement and immediate soothing and repair effects on the human body. After photorejuvenation, 15 minutes after using the facial mask provided in this application, the redness of the subjects' skin was significantly improved, and the barrier function was significantly restored, indicating that the facial mask provided in this application can quickly soothe the acute inflammatory response induced by the medical aesthetic procedure. The results of the consumer self-evaluation questionnaire showed that 100% of the subjects agreed that the facial mask provided in this application could effectively relieve the discomfort after photorejuvenation and accelerate the postoperative repair process. The realization of this immediate effect is mainly attributed to the rapid synergistic effect of panthenol and carboxymethyl deacetylated chitosan—the former quickly penetrates and inhibits the release of inflammatory factors, while the latter forms a biomimetic breathable membrane on the skin surface to physically isolate external stimuli. The two intervene at the beginning of the golden repair period after the procedure and effectively block the cascade amplification of inflammatory signals, thus gaining time for subsequent procedural repair. Combined with the aforementioned three-dimensional mechanism (energy activation—immune regulation—regeneration and reconstruction), it is further confirmed that the composition provided in this application achieves full-cycle coverage from immediate postoperative emergency care to long-term barrier homeostasis through the temporal connection and functional complementarity of the three components.

[0465] The above are merely preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A B5 composition with barrier-thickening and repairing effects, characterized in that, include: Hydrolyzed myrtle leaf extract raw materials, panthenol and carboxymethyl deacetylated chitosan; The mass ratio of the hydrolyzed myrtle leaf extract raw material, panthenol, and carboxymethyl deacetylated chitosan is 0.001~5:0.2~10:0.001~0.

5.

2. The B5 composition according to claim 1, characterized in that, The mass ratio of the hydrolyzed myrtle leaf extract raw material, panthenol, and carboxymethyl deacetylated chitosan is 0.01~2:0.3~5:0.002~0.

2.

3. The B5 composition according to claim 2, characterized in that, The mass ratio of the hydrolyzed myrtle leaf extract raw material, panthenol, and carboxymethyl deacetylated chitosan is 0.02~0.2:0.4~1:0.004~0.

02.

4. The B5 composition according to claim 3, characterized in that, The mass ratio of the hydrolyzed myrtle leaf extract, panthenol, and carboxymethyl deacetylated chitosan is 0.02:1:0.004 or 0.2:0.4:0.

02.

5. The B5 composition according to any one of claims 1 to 4, characterized in that, The hydrolyzed myrtle leaf extract raw materials include: 2.0wt%~10.0wt% hydrolyzed myrtle leaf extract; 5.0wt%~15.0wt% of 1,2-pentanediol; and the remaining water; The number-average molecular weight of the carboxymethyl deacetylated chitosan is 100,000 Da to 800,000 Da.

6. The use of the B5 composition according to any one of claims 1 to 5 in the preparation of products that soothe, repair, anti-aging, improve skin redness, improve transepidermal moisture loss, repair skin damaged after cosmetic procedures, and repair skin with a damaged barrier.

7. The application according to claim 6, characterized in that, The B5 composition enhances mitochondrial membrane potential and activates cellular energy metabolism; and / or, The B5 composition inhibits the release of pro-inflammatory factors, soothing redness, burning, and stinging; and / or, The B5 composition promotes the expression of inner lining protein and liposome protein, and repairs the skin barrier; and / or, The B5 composition promotes the secretion of type I collagen, improving skin firmness and elasticity.

8. A product with barrier-thickening and repairing effects, characterized in that, Includes the B5 composition according to any one of claims 1 to 5.

9. The product according to claim 8, characterized in that, For personal care products.

10. The product according to claim 9, characterized in that, For use as toner, lotion, cream, or mask.

Images